BioSpace News Archive

Hua Medicine, a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, announced post-analysis results from dorzagliatin’s 24-week monotherapy trial SEED,.

AVITA Medical Limited ACN 058 466 523 is pleased to announce that shareholders voted in favour of the scheme of arrangement to effect a redomiciliation of the Company and its subsidiaries from Australia to the United States of America, under which AVITA Therapeutics, Inc., a company incorporated in the State of Delaware in the United States of America, will become the parent company of the Avita Group.

Nanoform Finland Plc announced the appointment of Peter Hänninen as General Counsel, effective as of September 1, 2020.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that its abstract has been accepted for oral virtual presentation at the 3rd Annual Next Gen Immuno-Oncology Congress, which takes place from 25-26 June 2020.

AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®

Epsilen Bio, a biotechnology company developing transformative therapies for patients affected by underserved medical conditions through stable epigenetic silencing of genes involved in pathological processes, announced the appointments of Julia Berretta, Ph.D, as Chief Executive Officer, and Mathieu Simon, M.D., as Chairman of the Board.

Oncopeptides AB announces that the full top-line results from the pivotal phase 2 HORIZON study, evaluating intravenous melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma, have been presented at the ongoing 25th European Hematology Association meeting, EHA.

Added responsibilities underscore company’s focus on commercial growth for the IRRAflow® and Hummingbird product lines

Solasia Pharma K.K., a specialty pharmaceutical company based in Asia, announced the positive results from the pivotal Phase 2 study with SP-02 for relapsed or refractory peripheral T-cell lymphoma in Asia.

These Data Demonstrate Breadth of Takeda’s Portfolio and Pipeline with Three Hematology Presentations at the Virtual Summit